Secukinumab 2-weekly vs. 4-weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study.
Kristian ReichA KörberUlrich MrowietzMichael SticherlingC SiederJ FrühT BachhuberPublished in: The British journal of dermatology (2020)
Most patients achieved PASI 90 response with secukinumab q4w. There was potential benefit of q2w dosing in some suboptimal responders. Continued q4w treatment can improve response even after 16 weeks.
Keyphrases
- end stage renal disease
- ankylosing spondylitis
- newly diagnosed
- chronic kidney disease
- double blind
- coronary artery disease
- open label
- prognostic factors
- peritoneal dialysis
- randomized controlled trial
- clinical trial
- systemic lupus erythematosus
- patient reported outcomes
- human health
- placebo controlled
- replacement therapy